ClinicalTrials.gg
RecruitingNCT07669571Updated Sep 15, 2026

A Phase I Study of NS-079 in Healthy Participants

A Phase 1 interventional study of Placebo and NS-079 tablet in Healthy Adult Participants, sponsored by NeuShen Therapeutics. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by NeuShen Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are:

  • Is NS-079 safe and tolerable in heathy participants under tested dosing regimen?
  • What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.
02

Conditions studied

  • Healthy Adult Participants

Keywords

  • 5-HT2A receptor
03

In context

Lead sponsor

NeuShen Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females aged 18-55 years (inclusive), with a (BMI) between 18.00 and 32.00 kg/m2(inclusive) at screening.
  2. Not participated in any other clinical trials and received an drug or device within the past 30 days or 5 half-lives prior to screening, whichever is longer.
  3. Women of non- (WONCBP) (as defined in Appendix 1); women of childbearing potential (WOCBP) who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective (as defined in Appendix 1) in combination with a condom from the time of signing the form until at least 90 days after the last dose of investigational product, agree to refrain from ova donation during this period, and return a negative pregnancy test at screening and baseline (Day -1).
  4. Surgically sterile males (with verbal confirmation of the absence of sperm in the ejaculate); males who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective contraception with a female partner (as defined in Appendix 1) in combination with a condom from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and agree to refrain from sperm donation during this period.
  5. In good health, determined by the investigator/delegate on the basis of medical history, physical examinations, vital signs, (ECGs), clinical laboratory tests (hematology, coagulation, urinalysis, blood biochemistry). Repeated examination is allowed once per timepoint at the investigator/delegate's discretion.
  6. Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Participant voluntarily participates and signs the informed consent form before any study procedures begin.
  7. Agree to provide a biological sample (blood or saliva/buccal swab, per site capability) for Cytochrome P450 2D6 (CYP2D6) pharmacogenetic genotyping during the screening period, and the genotyping results must be available prior to randomization and dosing.
  8. Participants must be confirmed CYP2D6 Normal Metabolizers (NM) or Intermediate Metabolizers (IM) based on pharmacogenetic genotyping. For Part 3 [DDI] participants only: Must have a confirmed CYP2D6 NM status based on pharmacogenetic genotyping.

Exclusion criteria

Exclusion Criteria

  1. Known or allergy to the product, its , or any of its components, or a history of allergic reactions that, in the opinion of the investigator/delegate, may place the participant at increased risk.
  2. Known hypersensitivity to or severe intolerance of paroxetine or any SSRI (including serotonin syndrome or discontinuation syndrome) (for Part 3 [DDI] only).
  3. Unable to refrain from all known CYP2D6 substrate medications (including over-the-counter (OTC) medications such as dextromethorphan-containing cough and cold preparations) during paroxetine dosing (for Part 3 [DDI] only). Final clinical judgment on individual concomitant medications remains with the investigator/delegate.
  4. Individuals with a history of intolerance to venipuncture or venous catheterization (e.g., recurrent syncope during blood draws or significant needle phobia) that, in the opinion of the investigator/delegate, may interfere with the study procedures.
  5. Positive serologic test results for surface antigen (HBsAg), virus antibody (Anti-HCV) or antibody (Anti-HIV) at Screening.
  6. Average daily smoking of more than 5 cigarettes per day in the 3 months prior to Screening, or inability or unwillingness to abstain from the use of tobacco or nicotine-containing products (including cigarettes, e-cigarettes, vaping products, and nicotine replacement products) from 48 hours prior to the first dose through completion of the final safety follow-up visit.
  7. Excessive alcohol consumption, defined as average weekly alcohol intake exceeding 14 units during the 4 weeks prior to Screening (1 unit ≈10 g of pure alcohol; 1 alcohol unit is equal to 375ml 3.5% beer, 100 mL of wine, or 30 mL of 40% spirit), unwillingness or inability to abstain from alcohol and alcohol-containing products from 48 hours prior to the first dose through the completion of the final safety follow-up visit, or a positive alcohol breath test at Screening or upon admission to the clinical unit. (A repeat test may be performed once per timepoint at the investigator/delegate's discretion).
  8. Excessive consumption of caffeinated beverages (e.g., coffee, tea, energy drinks), defined as an average of >8 cups/day (1 cup ≈ 250 mL) within 3 months prior to screening, or unwillingness or inability to refrain from caffeinated beverages from 48 hours prior to the first dose through the end of the inpatient confinement phase.
  9. Unwillingness or inability to abstain from grapefruit or grapefruit containing products, Seville (bitter) oranges, or pomelo/pomelo-containing products from 7 days prior to the first dose through the end of the inpatient confinement phase.
  10. Use of classic psychedelics or hallucinogenic substances with primary 5-HT2A agonist activity (e.g., lysergic acid diethylamide [LSD], psilocybin/magic mushrooms, dimethyltryptamine [DMT], ayahuasca, mescaline) on 5 or more occasions lifetime, or any use within 5 years prior to Screening.
  11. Current or past substance use disorder (including alcohol or drugs of abuse) within the 12 months prior to Screening, as judged by the investigator/delegate; use of ketamine or phencyclidine (PCP) for recreational or non-prescribed purposes within 12 months prior to Screening; use of cannabis within 6 weeks prior to Screening; use of other illicit drugs or non-prescribed psychoactive substances (including but not limited to MDMA, cocaine, opiates, amphetamines) within 4 weeks prior to Screening; or a positive drug of abuse urine screen at Screening or upon admission. Single or occasional use prior to the applicable may be permitted at the investigator/delegate's discretion, provided the urine drug screen is negative. A repeat drug screen may be performed once per timepoint at the investigator/delegate's discretion.
  12. History or presence of the following conditions:

    1. . Clinically significant (as judged by the investigator/delegate) neurological or psychiatric disorders, defined as any of the following: history of epilepsy or any seizure disorder (excluding childhood febrile seizures); history of dementia or any clinically diagnosed cognitive disorder; clinically significant migraine, defined as: history of migraine with aura; chronic migraine (≥4 migraine days/month on average over the past 6 months); or use of prophylactic migraine medication or triptans within 30 days prior to first dose; any current or lifetime clinical diagnosis of schizophrenia spectrum or other psychotic disorder, bipolar I or II disorder, or borderline personality disorder; clinically significant depression, defined as: any current or lifetime clinical diagnosis of major depressive disorder or other depressive disorder; any history of pharmacological treatment for depression; any current clinical diagnosis of anxiety disorder or any history of pharmacological treatment for anxiety within 1 year prior to screening; or any history of psychiatric hospitalization. Neurological and psychiatric history will be assessed at Screening through clinical interview by the investigator/delegate, supplemented by review of available medical records.
    2. . Clinically significant (as judged by the investigator/delegate) cardiovascular disorders, including history of prolonged (defined as QTcF >450 ms for males or >470 ms for females, or any clinically significant abnormality); or chronic cardiovascular diseases (specifically including history of cardiac valvulopathy or pulmonary hypertension or hypertension); or current hypertension (resting systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg). Blood pressure assessment can be repeated at the discretion of the investigator/delegate.
    3. . Clinically significant (as judged by the investigator/delegate) systemic diseases or conditions, including immunodeficiency or disorders; malignant neoplastic diseases; or clinically significant endocrine, respiratory, hematologic (including coagulation), or digestive system diseases that may interfere with the safety of the participant or the interpretation of study results.
    4. . Any of the following laboratory or medical history findings: or ALT >2 × , or known or suspected Gilbert's Syndrome; \<60 ml/min/1.73m2; History of cholecystectomy.
  13. Family history of a psychotic disorder (including schizophrenia, schizoaffective disorder, or bipolar disorder) in a first-degree relative.
  14. Clinically significant (as judged by the investigator/delegate) current or past suicidality based on the Columbia-Suicide Severity Rating Scale (C-SSRS), or psychiatric history indicating current suicidal ideation, or a history of active suicidal ideation or suicide attempts.
  15. Underwent major surgery within the past 6 months prior to the first dose (such as coronary artery bypass grafting, hepatectomy, gynecological surgery, etc.)
  16. Occurrence of acute neurological, digestive, respiratory, cardiovascular, endocrine, hematological, or other systemic diseases that may affect the absorption, distribution, metabolism, excretion, and safety evaluation of the investigational product within 3 months prior to screening judged by investigator/delegate.
  17. Donation of blood or experienced blood loss ≥400 mL within the 3 months prior to the first dose; difficulties in venous blood collection; planned blood donation during the study or within 30 days after the study.
  18. Use of any prescription or non-prescription medications, including over-the-counter (OTC) medications within 14 days or 5 elimination half-lives (whichever is longer) prior to the first dose; use of any herbal products or nutritional/dietary supplements within 21 days prior to the first dose, except paracetamol (≤2 g per day); and use of any central nervous system acting drugs (including monoamine oxidase inhibitors [MAOIs], SSRIs), serotonergic supplements (e.g., St. John's Wort, 5-hydroxytryptophan [5-HTP], L-tryptophan), or strong/moderate CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine (prior use prohibited; protocol-directed administration as CYP2D6 index inhibitor in Part 3 [DDI] only), quinidine, terbinafine, duloxetine, cinacalcet) within 30 days or 5 elimination half-lives (whichever is longer) prior to the first dose. For Part 3 [DDI] only: Unwillingness or inability to abstain from NSAIDs (e.g., ibuprofen, naproxen, diclofenac) or aspirin throughout the paroxetine dosing and washout period; paracetamol (≤2 g/day) is the only permitted analgesic during this period.
  19. Receipt of vaccines within the 4 weeks prior to the first dose of the investigational product.
  20. Other factors deemed unsuitable for participation in the trial by the investigator/delegate.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    NS-079 Arm 1

    NS-079 SAD Dose 1

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 2

    NS-079 SAD Dose 2

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 3

    NS-079 SAD Dose 3

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 4

    NS-079 SAD Dose 4

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 5

    NS-079 SAD Dose 5

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 6

    NS-079 MAD Dose 1

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 7

    NS-079 MAD Dose 2

    Drug: NS-079 tablet

  • Experimental
    NS-079 Arm 8

    NS-079 MAD Dose 3

    Drug: NS-079 tablet

  • Placebo comparator
    Placebo Arm 9

    NS-079 SAD Dose 1 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 10

    NS-079 SAD Dose 2 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 11

    NS-079 SAD Dose 3 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 12

    NS-079 SAD Dose 4 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 13

    NS-079 SAD Dose 5 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 14

    NS-079 MAD Dose 1 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 15

    NS-079 MAD Dose 2 PBO

    Drug: Placebo

  • Placebo comparator
    Placebo Arm 16

    NS-079 MAD Dose 3 PBO

    Drug: Placebo

  • Experimental
    NS-079 Arm 17

    NS-079 DDI dose 1

    Drug: NS-079 tablet · Drug: Paroxetine

Interventions

  • DrugPlacebo

    NS-079 matching placebo

  • DrugNS-079 tablet

    Investigational product NS-079

  • DDI study treatment drug

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  2. Main pharmacokinetic parameters

    Cmax

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  3. Main pharmacokinetic parameters

    Cmax,ss

    Time frame: for MAD, day 1-14

  4. Main pharmacokinetic parameters

    NS-079-M1/NS-079 AUC ratio as an in vivo CYP2D6 fm biomarker

    Time frame: For DDI, Day 1- 30

  5. Main urine pharmacokinetic parameters

    Ae

    Time frame: For SAD, Day 1-4; for DDI, day 1-30

  6. Main pharmacokinetic parameters

    NS-079-M1/NS-079 Ae ratio

    Time frame: For DDI, day 1-30

  7. Main pharmacokinetic parameters

    AUC0-∞

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  8. Main pharmacokinetic parameters

    AUC0-t

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  9. Main pharmacokinetic parameters

    Tmax

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  10. Main pharmacokinetic parameters

    t1/2

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  11. Main pharmacokinetic parameters

    CL/F

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  12. Main pharmacokinetic parameters

    Vd/F

    Time frame: for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

  13. Main pharmacokinetic parameters

    Cmin,ss

    Time frame: for MAD, day 1-14

  14. Main pharmacokinetic parameters

    Tmax,ss

    Time frame: for MAD, day 1-14

  15. Main pharmacokinetic parameters

    Cavg,ss

    Time frame: for MAD, day 1-14

  16. Main pharmacokinetic parameters

    AUCss,0-tau

    Time frame: for MAD, day 1-14

  17. Main pharmacokinetic parameters

    AUCss,0-∞

    Time frame: for MAD, day 1-14

  18. Main pharmacokinetic parameters

    CLss/F

    Time frame: for MAD, day 1-14

  19. Main pharmacokinetic parameters

    accumulation factor (Rac)

    Time frame: for MAD, day 1-14

  20. Main pharmacokinetic parameters

    DF

    Time frame: for MAD, day 1-14

  21. Main urine pharmacokinetic parameters

    Ae%

    Time frame: For SAD, Day 1-4; for DDI, day 1-30

  22. Main urine pharmacokinetic parameters

    CLr

    Time frame: For SAD, Day 1-4; for DDI, day 1-30

  23. Main urine pharmacokinetic parameters

    ER

    Time frame: For SAD, Day 1-4; for DDI, day 1-30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 25, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07669571
Lead sponsor
NeuShen Therapeutics
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jul 30, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Jin Lili, MS
Contact
lili.jin@neushen.com
+86 13918207440

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion